Business Description
Guerbet SA
ISIN : FR0000032526
Share Class Description:
CHIX:GBTp: Ordinary SharesTotal Employee Number:
2,746Compare
Compare
Traded in other countries / regions
GBT.France4G8.Germany0ELV.UKGURBF.USA IPO Date
2013-07-15Description
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.65 | |||||
Debt-to-EBITDA | 6.08 | |||||
Interest Coverage | 0.41 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.94 | |||||
Beneish M-Score | -3.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.2 | |||||
3-Year EBITDA Growth Rate | -9.9 | |||||
3-Year EPS without NRI Growth Rate | -67.6 | |||||
3-Year Book Growth Rate | -11.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.22 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.49 | |||||
Quick Ratio | 1.27 | |||||
Cash Ratio | 0.6 | |||||
Days Inventory | 482.02 | |||||
Days Sales Outstanding | 72.66 | |||||
Days Payable | 145.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -19.59 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.89 | |||||
Operating Margin % | 1.01 | |||||
Net Margin % | -13.56 | |||||
EBITDA Margin % | 9.09 | |||||
FCF Margin % | 5.57 | |||||
OCF Margin % | 10.15 | |||||
ROE % | -31.33 | |||||
ROA % | -10.89 | |||||
ROIC % | 1.05 | |||||
3-Year ROIIC % | 64.88 | |||||
ROC (Joel Greenblatt) % | -16.57 | |||||
ROCE % | -12.05 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 115.48 | |||||
Shiller PE Ratio | 8.79 | |||||
Price-to-Owner-Earnings | 4.95 | |||||
PS Ratio | 0.14 | |||||
PB Ratio | 0.42 | |||||
Price-to-Tangible-Book | 0.54 | |||||
Price-to-Free-Cash-Flow | 2.51 | |||||
Price-to-Operating-Cash-Flow | 1.38 | |||||
EV-to-EBIT | -4.47 | |||||
EV-to-EBITDA | 5.52 | |||||
EV-to-Revenue | 0.5 | |||||
EV-to-FCF | 9.01 | |||||
Price-to-GF-Value | 0.45 | |||||
Price-to-Projected-FCF | 0.26 | |||||
Price-to-Median-PS-Value | 0.25 | |||||
Earnings Yield (Greenblatt) % | -22.37 | |||||
FCF Yield % | 40.29 | |||||
Forward Rate of Return (Yacktman) % | 21.71 |
Guerbet SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guerbet SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 4:1 Stock Split | 2014-01-23 | 27.83 (+0.53%) |
Show
Entries
Press Release
Articles on Guerbet SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers